Literature DB >> 17377351

Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection.

H D J Daniel1, P Vivekanandan, S Raghuraman, G Sridharan, G M Chandy, P Abraham.   

Abstract

PURPOSE: To evaluate the role of core antigen (Ortho trak-C assay) as a marker of active HCV infection in comparison to HCV RNA as detected by reverse transcription polymerase chain reaction (RT-PCR).
METHODS: This evaluation was carried out during January 2000 to December 2003 in HCV infected individuals who were treatment naomicronve or were on anti-viral therapy. Additionally, sequential plasma samples from patients on clinical follow-up were included in this study. A total of 167 samples from 61 patients were tested by trak-C and RT-PCR. HCV RNA detection was achieved by a RT-PCR. Trak-C assay results were also compared in a limited proportion of these samples with known HCV viral load and genotype.
RESULTS: Of 167 samples tested, 56.9% were RNA positive and 43.1% were RNA negative while 50.3% were trak-C positive and 49.7% were trak-C negative, yielding a sensitivity of 85.3% and a specificity of 95.8% for the trak-C assay (Kappa co-efficient = 0.8). The concentration of HCVcAg and HCV RNA showed significant correlation (n=38, r=0.334, P =0.04). The trak-C assay detected the most prevalent HCV genotypes in India without significant difference (P =0.335). The difference between mean absorbance values of HCV RNA positive samples compared to HCV RNA negative samples in the trak-C assay was highly significant (P < 0.000). Qualitative results of trak-C assay and RT-PCR were comparable in 93% of follow-up samples.
CONCLUSIONS: Trak-C assay can be recommended for confirmation of HCV infection and follow-up in laboratories with resource-poor facilities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377351     DOI: 10.4103/0255-0857.31060

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  8 in total

Review 1.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

2.  Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results.

Authors:  Recep Kesli; Hakki Polat; Yuksel Terzi; Muhammet Guzel Kurtoglu; Yavuz Uyar
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

Review 3.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.

Authors:  Pankaj Puri; Vivek A Saraswat; Radha K Dhiman; Anil C Anand; Subrat K Acharya; Shivaram P Singh; Yogesh K Chawla; Deepak N Amarapurkar; Ajay Kumar; Anil Arora; Vinod K Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Gaurav Pandey; Rohan Malik; Swastik Agrawal
Journal:  J Clin Exp Hepatol       Date:  2016-07-02

4.  Hepatobiliary Quiz (Answers)-16 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-12-21

5.  Core antigen tests for hepatitis C virus: a meta-analysis.

Authors:  Shuijun Gu; Jun Liu; Huijun Zhang; Baoluo Gu; Hanjiang Lai; Hongliang Zhou; Chaoqi He; Yingying Chen
Journal:  Mol Biol Rep       Date:  2012-04-29       Impact factor: 2.316

Review 6.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-24

7.  HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b.

Authors:  Zhijuan Fan; Junfeng Liu; Fengmei Wang; Jingmin Liu; Xian Ding; Shuye Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

8.  Improving Diagnosis of Hepatitis C Virus Infection Using Hepatitis C Core Antigen Testing in a Resource-Poor Setting.

Authors:  Ayswarya Kannan; Lalitha Biswas; Anil Kumar; Jessy Kurian; Anjaly S Nair; Parasmal Suresh; Shine Sadasivan; Raja Biswas
Journal:  Rev Soc Bras Med Trop       Date:  2021-02-10       Impact factor: 1.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.